Halbert Hargrove Global Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1	Closed	-$320	–	374
2026 Q2	$320	Buy	+1	New	+$302	﹤0.01%	592
2025 Q4	–	Sell	-23	Closed	-$10.5K	–	383
2025 Q3	$10.5K	Buy	+23	New	+$9.37K	﹤0.01%	329
2025 Q2	–	Sell	-1	Closed	-$271	–	328
2025 Q1	$271	Buy	+1	New	+$257	﹤0.01%	565

Other funds holding ALNY

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Halbert Hargrove Global Advisors's ALNY Position: Q3 2026 in Review

Halbert Hargrove Global Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 1 share — an estimated $320 sold.

Halbert Hargrove Global Advisors first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $10.5K in Q3 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Halbert Hargrove Global Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Halbert Hargrove Global Advisors sold 1 Alnylam Pharmaceuticals share in Q3 2026, an estimated $320.
Halbert Hargrove Global Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Halbert Hargrove Global Advisors's Alnylam Pharmaceuticals position peaked at $10.5K in Q3 2025.
591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Halbert Hargrove Global Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.